Neurology
-
Randomized Controlled Trial Clinical Trial
TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.
A double-blind, placebo-controlled phase II study was conducted in 168 patients, most with relapsing-remitting MS, to evaluate whether lenercept would reduce new lesions on MRI. ⋯ Lenercept failed to be beneficial, but insight into the role of TNF in MS exacerbations was gained.